Eurobio Scientific: Results for the first semester of fiscal year 2026

Eurobio Scientific reported H1 FY2026 revenue of €84.5 million, up 4.5% year on year, while EBITDA rose 20% to €15.8 million and net income nearly doubled to €4.7 million. Proprietary-product revenue increased 10% to €31.3 million, lifting its mix to 37%, and free cash flow reached €4.0 million despite a €5.0 million working-capital outflow. The company completed its CareDx Lab Solutions acquisition, financed largely by €154.4 million from majority shareholder EB Development, which has proposed a €25.30-per-share tender offer and subsequent squeeze-out. A key risk is Seegene's planned direct entry into France from January 2027, though Eurobio retains certain existing contract rights during the transition.

Analysis

ALERS is no longer a conventional earnings-driven equity: with the controller above the squeeze-out threshold, the relevant valuation question is whether the independent expert supports €25.30 rather than whether reported operating leverage warrants a higher public-market multiple. Liquidity should progressively deteriorate during the AMF review, making a discount-to-offer trade potentially attractive but unsuitable for size given Euronext Growth execution risk and a finite regulatory timetable. The key near-term catalyst is the fairness opinion/AMF clearance; the principal downside is a process delay or an adverse valuation conclusion, not a deterioration in the next quarterly print.

The operational result is less durable than headline profit growth implies. Organic group revenue is flat while legacy third-party distribution is contracting, so margin defense depends on proprietary transplant assays scaling rapidly enough to absorb both lost tender business and the 2027 Seegene channel transition. CareDx Lab Solutions adds strategically coherent transplant assets, but the €154m related-party funding creates a high hurdle: the acquired business must produce meaningful incremental EBITDA and working-capital conversion before it can offset the earnings concentration represented by the expiring distribution relationship. The shareholder loan also reduces the practical benefit of reported cash generation to minority holders.

For CDNA, the divestiture is directionally favorable only if Lab Solutions was dilutive to its core transplant-testing economics or consumes disproportionate commercial/infrastructure cost. Investors should not extrapolate this asset sale into a material near-term CDNA earnings catalyst without disclosed consideration, stranded-cost treatment, and transition-service details; the more relevant read-through is whether CDNA is narrowing toward higher-return testing and digital monitoring assets. Contrarianly, ALERS' proprietary-product mix shift may be real, but it is not yet sufficient evidence that the company has replaced the gross-profit pool at risk from Seegene after 2027.

Key Decisions for Investors

• ALERS: monitor the discount to the €25.30 proposed cash consideration; initiate only if the annualized spread exceeds roughly 12-15% with AMF documentation accepted and no fairness-opinion objection. Size small because free float is below 10% and exit liquidity can disappear; upside is spread convergence, downside is process delay/repricing risk.
• Do not underwrite a standalone ALERS long beyond the tender price. Reassess only if management discloses CareDx Lab Solutions revenue, EBITDA, purchase accounting, and integration costs; require evidence that acquired EBITDA plus proprietary-product growth can cover a material portion of the 2027 Seegene revenue/profit exposure.
• CDNA: remain neutral pending sale economics. Set an alert for transaction proceeds, stranded costs, and any revision to operating-expense guidance; a long is justified only if disposal proceeds reduce cash burn or management lifts gross-margin/EBITDA trajectory without lowering transplant-testing growth expectations.
• For ALERS event-risk holders, treat AMF clearance and the independent appraiser's fairness range as the binary catalyst over the next 1-3 months; exit if the offer timetable slips materially, the appraiser identifies value above the offer without a revised bid, or transition terms imply a faster-than-expected Seegene revenue runoff.